The expert panel consider the use of IDegAsp in insulin-naïve T2D patients with poor glycemic control (HbA1c >8.5%) despite optimal OADs as well as in insulin-treated T2D patients by switching from basal insulin, basal-bolus therapy or premixed insulins in relation to lower risk of nocturnal hypoglycemia, fewer injections and lower intraday glycemic variability, respectively. The gene discussed is INS; the disease is type 2 diabetes mellitus.